Hemostemix (HEM) Stock Price, News & Analysis

Company Overview

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Key Stats

• Today's Range: C$0.13 to C$0.14
• 50-Day Range: C$0.08 to C$0.15
• 52-Week Range: C$0.04 to C$0.43
• Volume: 72,300 shs
• Average Volume: 423,049 shs
• Market Capitalization: C$19.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HEM Stock Analysis - Frequently Asked Questions

How have HEM shares performed this year?

Hemostemix's stock was trading at C$0.12 at the beginning of 2025. Since then, HEM shares have increased by 12.5% and is now trading at C$0.14.
View the best growth stocks for 2025 here.

How do I buy shares of Hemostemix?

Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Hemostemix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Golden Share Resources (GSH), Nuvilex (PMCB), Algernon Pharmaceuticals (AGNPF), Defense Metals (DFMTF) and NIO (NIO).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:HEM
• CIK: N/A
• Web: www.hemostemix.com
• Phone: +1-403-3409207
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$5.00 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 37.07%
• Return on Assets: -349.24%

Debt

• Debt-to-Equity Ratio: -55.07
• Current Ratio: 0.04
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 10.77
• Book Value: C($0.10) per share
• Price / Book: -1.36

Miscellaneous

• Outstanding Shares: 145,727,000
• Free Float: N/A
• Market Cap: C$19.67 million
• Optionable: Not Optionable
• Beta: 0.20